glp 1 vs glp 1ra GLP-1 Genetics: How Genes Affect Appetite, Semaglutide, and Tirzepatide Response Emerging Trends in the Development

Transient firing of dorsal raphe neurons encodes diverse and specific sensory, motor, and reward events

For instance, in August 2025, Viking Therapeutics, a US-based company specializing in metabolic and endocrine disorder treatments, announced positive top-line results from its Phase 2 VENTURE-Oral Dosing trial of VK2735, an investigational oral dual GLP-1/GIP agonist for obesity

Quality of the peptide and quality of the oversight are inseparable

Fenofibrate-associated nephrotoxicity: a review of current evidence

In traditional clinical trials, a "responder" is someone who loses at least 5% of their body weight within the first three to six months

Sawai K, Mukoyama M, Mori K et al (2007) Expression of CCN1 (CYR61) in developing, normal, and diseased human kidney